Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.